MUMBAI, India, Sept. 21, 2021 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc. According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately $12.0 million*. Glenmark"s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA"s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. References: 1All brand names and trademarks are the property of their respective owners. 2Market includes brand and all available therapeutic equivalents *IQVIATM National Sales Perspectives: Retail & Non-Retail, July 2021 About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark"s key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world"s top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa"s Generics Bulletin). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world"s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg PWR PWR